Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Biotechnology

Other Health

Health

Pharmaceutical

General Health

Other Science

Science

Forge Biologics

More Like This

Forge Biologics Announces the FUEL™ AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production

The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria

Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation

Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1

PR Newswire associated0

AAVnerGene Announces AAVone®2.1, a Next-Generation Single-Plasmid AAV Production Platform Achieving ~1e16 GC/L and >70% Full Capsids at Harvest

PR Newswire associated0

Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases

PR Newswire associated0

Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality

PR Newswire associated0

Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deﬁciency Disorder